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Abstract 20 
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a 21 
unique mode of action, i.e. peptidoglycan degradation. However, Gram-negative pathogens are 22 
generally not susceptible due to their protective outer membrane. The concept of Artilysin®s 23 
overcomes this barrier. Artilysin®s are optimized, engineered fusions of selected endolysins with 24 
specific outer membrane destabilizing peptides. Artilysin® Art-175 comprises a modified variant of 25 
endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high 26 
susceptibility of P. aeruginosa for Art-175. Here, we report that Art-175 is highly bactericidal against 27 
stationary phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete 28 
elimination of large inocula (≥ 108 CFU/ml). Besides actively-dividing cells, also persisters are killed. 29 
Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after 30 
immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through 31 
osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM 32 
EDTA. No resistance development against Art-175 under selection pressure or no cross-resistance 33 
with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly 34 
active Artilysin® against both A. baumannii and P. aeruginosa, two of the most life-threatening 35 
pathogens of the order of the Pseudomonadales. 36 
 37 
  38 
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Introduction  39 
Acinetobacter baumannii is a Gram-negative, opportunistic pathogen which has become one of the 40 
most important pathogens responsible for hospital-acquired infections including urinary tract 41 
infections, secondary meningitis, (burn) wound infections, and ventilator-associated pneumonia. 42 
Particularly, patients admitted to the intensive care units are affected. Treatment options are 43 
becoming increasingly limited due to the ongoing spread of antibiotic resistance mechanisms. 44 
Combined with a high intrinsic resistance, this has resulted in the emergence of multidrug-resistant 45 
clinical isolates, leaving colistin as the only therapeutic option. However, an outbreak of pandrug-46 
resistant (including colistin) strains has been recently reported in Spain (1–3). The presence of a 47 
protective outer membrane limits not only the passage or diffusion of many currently available 48 
therapeutic antibiotics, most novel antibiotics in the development pipeline are too large to pass this 49 
barrier (4). A. baumannii infections often have a chronic nature, which can be attributed to the 50 
formation of persister cells, a small fraction of phenotypic variants highly tolerant to different classes 51 
of antibiotics (5, 6). For many antibiotics, persisters remain unaffected because of their dormant, non-52 
dividing and metabolically quiescent state. They are, however, also tolerant to antibiotics targeting 53 
non-dividing cells and evidence is accumulating that dormancy is not the only reason for the observed 54 
tolerance. The role of active mechanisms, such as those related with the suppression of oxidative 55 
stress, is currently gaining more support (7–9). When antibiotic treatment ceases, persisters may 56 
resuscitate and initiate a new infection. Eradication of persisters would thus lead to an improved long-57 
term recovery  (6, 10).  58 
We have recently reported the development of a novel class of enzyme-based antibacterials, coined 59 
Artilysin®s (11). Their mode of action relies on the fast enzymatic degradation of peptidoglycan by 60 
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endolysins, resulting in osmotic lysis. Endolysins are produced by bacterial viruses (or 61 
bacteriophages). At the end of the infection cycle, they pass the cytoplasmic membrane through holes 62 
formed by small membrane proteins (holins) in a precisely timed manner, causing a sudden lysis of 63 
the infected host cell to disperse the newly formed viral particles (12). Exogenous addition of 64 
recombinantly produced endolysin molecules are successfully being used to kill Gram-positive 65 
pathogens, but they are too large to pass the outer membrane of Gram-negative bacteria such as P. 66 
aeruginosa and A. baumannii. Artilysin®s consist of optimized fusions of a selected endolysin and a 67 
specific lipopolysaccharide (LPS) destabilizing peptide that effectively facilitates the outer membrane 68 
translocation of the endolysin moiety, eventually resulting in a physical cell lysis (13).  69 
In this study, the antibacterial effect of Artilysin® Art-175 is analyzed against highly prevalent 70 
epidemiological clones of multidrug-resistant A. baumannii and persisters thereof. Art-175 combines 71 
a mutated variant of endolysin KZ144, encoded by the giant P. aeruginosa bacteriophage φKZ, and the 72 
sheep myeloid antibacterial peptide 29 (SMAP-29). Art-175 has previously been shown to be highly 73 
bactericidal against multidrug-resistant P. aeruginosa with no cross-resistance with existing resistance 74 
mechanisms of 21 different antibiotics. In addition, resistant strains could not be selected after serial 75 
exposure to sub-inhibitory doses of Art-175 (14). In this study, we found that Art-175 represents a 76 
highly active antibacterial capable of killing large inocula of multidrug-resistant stationary phase cells 77 
of A. baumannii, including their persisters, with a high killing rate. 78 
 79 
 80 
 81 
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 82 
Material and methods 83 
Bacterial strains and culture conditions  84 
A. baumannii strains used in this study are presented in Table S1. Eighteen strains were received from 85 
the Ruhr-universität Bochum (Nationales Referenzzentrum für gramnegative Krankenhauserreger), 86 
one A. baumannii and one A. lwoffiii strain were received from the Universitätsklinikum Regensburg 87 
and seven strains from the Queen Astrid Military Hospital, Brussels (15). All strains were grown in 1:20 88 
Tryptic Soy Broth (TSB), unless mentioned otherwise, while shaking at 30°C. For solidified medium, 89 
1.5% agar was added to TSB. 90 
 91 
MIC determination  92 
Minimum inhibitory concentrations (MIC) for Art-175 (0.25-20 µg/ml), ciprofloxacin (Sigma-Aldrich) 93 
(0.01-17 µg/ml) and tobramycin (0.125-64 µg/ml) were determined by the microdilution method in 94 
96-well microtiter plates, according to the CLSI guidelines. The respective overnight bacterial cultures 95 
were adjusted to 0.5 McFarland standard, corresponding to 1 x 108 CFU/ml (OD625 ~ 0.08-0.1). 96 
Dilutions (100x) were made in 2x Mueller Hinton (MH) medium with or without 0.5 mM EDTA-Na2 to 97 
obtain a start inoculum of 1 x 106 CFU/ml. Bacterial cultures were distributed over the required 98 
number of wells and 50 µl volumes of cells were incubated for 24 h in the presence of 50 µl of a 2-fold 99 
dilution series of Art-175 or antibiotic, prepared in 20 mM HEPES-NaOH 100 mM NaCl pH 7.4. 2x MH 100 
medium (0.5 mM EDTA-Na2) with cells and 2x MH medium (0.5 mM EDTA-Na2) with 50 µl 20 mM 101 
HEPES-NaOH 100 mM NaCl pH 7.4 were included as positive and negative control, respectively. MIC 102 
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values were determined as the minimum concentration where no bacterial growth was detected. MIC 103 
values for colistin were determined with the Etest® strips for colistin of bioMerieux SA (Marcy l’Etoile, 104 
France) according to the manufacturer’s instructions. 105 
 106 
Antibacterial assay  107 
 A. baumannii overnight cultures were diluted 100x in 50 ml 1:20 Tryptic Soy Broth (TSB) and grown 108 
overnight (18 h) to achieve stationary phase cultures. RUH134 was selected as a reference strain and 109 
the MIC of ciprofloxacin, tobramycin and Art-175 in the presence of 0.5 mM EDTA were determined 110 
as 0.5 µg/ml, 2 µg/ml and 2 µg/ml, respectively. Stationary phase cultures of RUH875, LUH5875, 111 
RUH134 and NCTC 13423 were treated with 5x to 30x MICRUH134 concentrations of ciprofloxacin, 112 
tobramycin, Art-175 or the mixture of Art-175 with these antibiotics in total volumes of 200 µl, both 113 
in the presence and the absence of 0.5 mM EDTA-Na2. After 20’, 40’,1 h, 2 h or 24 h  for RUH134 and 114 
1 h or 24 h for RUH875, LUH5875 and NCTC 13423, respectively, treated cultures were washed in 20 115 
mM HEPES-NaOH pH 7.4 and appropriate dilutions were plated on TSB agar plates. Colonies were 116 
counted after 48 h of growth at 37°C. Each experiment was repeated independently at least three 117 
times. 118 
 119 
Persister killing   120 
Persister cells were isolated from a stationary phase culture as described previously, with minor 121 
modifications (16). An overnight culture of A. baumannii RUH134 was inoculated in 50 ml 1:20 TSB. 122 
After 18 h of growth at 37°C, the culture was treated with 60x MIC concentrations of tobramycin for 5 123 
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h at 37°C, while shaking at 200 rpm. Persister cells surviving antibiotic treatment were isolated by 124 
centrifugation (5250 x g, 15 min, 4°C) and the cell pellet was washed twice with 20 mM HEPES-NaOH 125 
pH 7.4. Cells were resuspended in 1:10 the initial volume of 20 mM HEPES-NaOH pH 7.4 after which a 126 
killing assay was performed as described previously (17), with minor modifications. A volume of 100 µl 127 
of the isolated persister fraction was mixed with ciprofloxacin, Art-175 (final concentrations of 30x 128 
MIC) or an equimolar amount of KZ144, in the absence or presence of 0.5 mM EDTA-Na2 (final 129 
concentration). Control treatments with Art-175 storage buffer (20 mM HEPES-NaOH 0.5 M NaCl pH 130 
7.4), 0.5 mM EDTA and tobramycin (30x MIC) were performed in parallel. The mixtures were shaken 131 
(200 rpm) for 1 h at 37°C. Treated persister cells were washed twice with 20 mM HEPES-NaOH pH 7.4, 132 
appropriate dilutions were plated on TSB agar plates and incubated at 37°C. The number of surviving 133 
persister cells was determined after 72 h incubation to allow complete resuscitation of all surviving 134 
persisters. Each experiment was independently repeated at least three times. 135 
 136 
Time-lapse microscopy  137 
A. baumannii RUH134 cells were grown to mid-exponential phase (OD600 = 0.6) in lysogeny broth (LB) 138 
at 37°C, washed three times with 20 mM HEPES-NaOH pH 7.4 (for cells with high turgor pressure) or 139 
20 mM HEPES-NaOH 0.5 M NaCl pH 7.4 (for cells without turgor pressure), and finally concentrated 140 
five times by resuspension in the corresponding wash buffer, supplemented with 0.5 mM EDTA-Na2. 141 
Cells were kept on ice until use. Bacterial cells (with high or low turgor pressure) were loaded into a 142 
ONIX B04A-03 Microfluidic Plate (EMD Millipore Corporation, Hayward, CA, USA), placed under the 143 
microscope and subsequently exposed to Art-175 to monitor cell inactivation and lysis. Art-175 (0.4 144 
mg/ml) was dialyzed before use against 20 mM HEPES-NaOH pH 7.4 (for cells with high turgor 145 
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pressure) or 20 mM HEPES-NaOH 0.5 M NaCl pH 7.4 (for cells with a lower turgor pressure) and was 146 
supplemented with 50 mM EDTA-Na2 to a final concentration of 0.5 mM EDTA-Na2. Visualization of 147 
cells with high turgor pressure was done by immobilization of the cells in the inlet channel of Art-175 148 
to ensure high Art-175 concentrations. The cells with lower turgor pressure, however, were visualized 149 
in the mid of the flow cell where due to diffusion effects the concentration of Art-175 is lower. Time-150 
lapse microscopy experiments were performed in a temperature controlled (Okolab, Ottaviano, Italy) 151 
Eclipse Ti-E inverted microscope (Nikon, Champigny-sur-Marne, France), equipped with a Ti-CT-E 152 
motorized condenser and a CoolSNAP HQ2 FireWire CCD camera (18). Images were acquired using 153 
NIS-Elements (Nikon), and the resulting pictures were further handled with open-source software, 154 
ImageJ (http://rsbweb.nih.gov/ij/). The CellASIC® ONIX Microfluidic System was operated using the 155 
CellASIC® ONIX FG Software, provided by the supplier (EMD Millipore Corporation). 156 
 157 
Resistance development   158 
The MIC of Art-175 and ciprofloxacin was determined against A. baumannii RUH134, RUH875 and 159 
LUH5875 as described above. Briefly, cultures were grown in Mueller Hinton broth and adjusted to 5 x 160 
105 CFU/ml. Two-fold dilution series of Art-175 and ciprofloxacin were prepared in 20 mM HEPES-161 
NaOH 100 mM NaCl pH 7.4 in a round bottom 96-well microtiter plate, in the presence of the 162 
bacterial cells and a final concentration of 250 µM EDTA. After 24 h, the MICs were recorded as the 163 
minimal concentration that completely inhibited growth. A new cycle was initiated for each 164 
strain/compound combination using a 100x dilution of cell suspensions at the highest concentration 165 
with full growth. This was repeated for 20 cycles. 166 
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 168 
Hemolytic assay  169 
A standardized hemolytic assay was performed by Pharmacelsus® GmbH to assess the level of 170 
erythrocyte damage caused by Art-175. Human erythrocytes were exposed to increasing 171 
concentrations of Art-175 for 0.5 – 4 hours on an orbital shaker. Positive controls consisted of 2% 172 
Tween 80 and 2% Triton-X100; 20 mM HEPES-NaOH 0.5 M NaCl pH 7.4 was used as negative control. 173 
The hemolytic effect of Art-175 was determined as the fraction of hemolysis relative to that of 2% 174 
Triton-X100. 175 
Results 176 
Art-175 is an effective antibacterial against relevant A. baumannii strains 177 
Growth inhibition by Art-175 was tested against a panel of thirty-three A. baumannii strains and one 178 
A. lwoffii strain from different sources, containing both lab strains and clinical (multidrug-resistant) 179 
isolates (Table S1). MICs of Art-175 range between 4 µg/ml and 20 µg/ml, showing the broad 180 
inhibitory activity of Art-175 against different (multidrug-resistant) A. baumannii strains. Addition of 181 
200 µM of EDTA reduced the MIC value of Art-175 and improved its antibacterial effect for all strains 182 
tested (ranging from ≤4 to 10 µg/ml), providing a potentially interesting feature for topical 183 
applications. Colistin resistance (>2-4 µg/ml) arises through addition of phosphoethanolamine or 4-184 
amino-4-arabinose to the phosphate groups of lipid A moiety of the lipopolysaccharides (19, 20) and 185 
may thus directly affect the susceptibility for Art-175. However, no correlation was found between 186 
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the MIC values for colistin and Art-175, respectively (n=28; R²=0.0043), indicating the lack of cross-187 
resistance (Table S2).  188 
The increased number of outbreaks of A. baumannii infections in clinical settings, which often share a 189 
genetic background, is believed to be linked to the global spread of a number of highly successful 190 
clones (21, 22). The strains tested in this study include the reference strains of EU clones I (RUH875), II 191 
(RUH134) and III (LUH5875) and the NCTC 13423 strain with MIC values of  8 µg/mL, 10 µg/mL, 12 192 
µg/mL and 6 µg/mL, respectively, all multidrug-resistant strains showing resistance against 193 
aminoglycosides, quinolones and carbapenems  (15). The NCTC 13423 or T strain was first isolated in 194 
2003 from a casualty returning from the Iraqi war, deeming it the nickname ‘Iraqibacter’. Despite not 195 
having greatly contributed to an increase in A. baumannii infections, it possesses all characteristics of 196 
a highly successful outbreak strain and has become a major cause of concern in conflict zones (23, 197 
24).  In sum, Art-175 shows a good antibacterial activity against all tested A. baumannii strains, 198 
independent of the presence of multidrug-resistance mechanisms. 199 
 200 
Art-175 outcompetes conventional antibiotics in bactericidal activity and killing rate against A. 201 
baumannii 202 
Time-kill experiments were done for Art-175 and compared to those of ciprofloxacin and tobramycin, 203 
two first-line antibiotics against A. baumannii infections (Figure 1A-B). Stationary phase cultures of 204 
RUH134, RUH875, LUH5875 and NCTC 13423 (~107 – 108 CFU/ml) were treated for 1 and 24 h with 205 
30x MICRUH134 concentrations of Art-175, ciprofloxacin or tobramycin. A single dose of Art-175 206 
eradicated all strains completely within 24 h (approximately 8 – 9 log reduction) with a strain-207 
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dependent killing rate. RUH875 was already completely eliminated after 1 h, while RUH134 and NCTC 208 
13423 still showed a minute surviving fraction (approximately 7 – 8 log reduction), which was 209 
completely eliminated after 24 h. Art-175 had the slowest antibacterial effect against LUH5875, with a 210 
2.5 log reduction after 1 h. The bactericidal effect of an Art-175 treatment significantly exceeded the 211 
effect of either ciprofloxacin or tobramycin, both in extent and rate. Ciprofloxacin and tobramycin 212 
killed between 1.0 and 4.5 log in 24 hours, with the exception of RUH134 and NCTC 13423. Both 213 
strains were completely eliminated by tobramycin after 24 hours, but still at a slower rate than in the 214 
case of Art-175 (Figure 1A-B). 215 
 216 
Subsequently, the effect of the combination of a conventional and experimental antibacterial was 217 
evaluated to assess the usefulness of Art-175 as a supplement to currently used antibiotics and to 218 
exclude possible antagonistic effects (Figure 1A-B). The same four strains were exposed to either a 219 
mixture of Art-175 and tobramycin or Art-175 and ciprofloxacin (each 30x MIC). The antibacterial 220 
effect of the mixtures was significantly better (P<0.005) than the respective conventional antibiotics 221 
alone. No significant differences (P>0.05) were observed compared to Art-175 treatment alone. 222 
However, one exception is observed; strain LUH5875, which was affected by Art-175 at a slower rate 223 
compared to the three other strains, was killed faster by a mixture of ciprofloxacin and Art-175 (4 log 224 
reduction after 1 h) than by Art-175 alone (2.5 log reduction after 1 h). After 24 h of treatment with 225 
both combinations, the surviving fractions of all bacterial strains tested were reduced to well below 226 
the detection limit. In conclusion, the efficacy of a mixture of Art-175 and ciprofloxacin/tobramycin is 227 
comparable to Art-175 alone. No antagonistic effects are observed, and it is likely that most cells are 228 
already killed by Art-175 before ciprofloxacin and tobramycin can exert their action. 229 
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 230 
To gain insight in the high killing rate of Art-175, additional time-kill curves were determined for 231 
stationary phase cells of RUH134 in a shorter time frame (after 20 min, 40 min, 1 h and 2 h) (Figure 232 
1C). While the killing rate for ciprofloxacin is low, all other treatments lead to a fast killing, which is 233 
most pronounced for Art-175 and the combinations of Art-175 with either ciprofloxacin or 234 
tobramycin. Within 20 minutes, reductions between 4.5 and 6.5 log are observed and complete killing 235 
is effectively reached within two hours. Again, no significant differences are observed between Art-236 
175 alone and combinations of ciprofloxacin or tobramycin with Art-175. These findings confirm the 237 
rapid killing rate of Art-175 and show that, even when large inocula of stationary phase cells are used, 238 
complete eradication can be achieved in a short time (2 h). 239 
 240 
To evaluate the dose-dependence of the antibacterial effect exerted by Art-175 in the absence of 0.5 241 
mM EDTA, RUH134 was exposed to increasing concentrations of Art-175 for 20 min, 40 min, 1 h and 2 242 
h (Figure 1D). A clear dose- and time-dependent effect is observed with significant killing starting from 243 
10x MIC Art-175. After 2 h of treatment reductions of 0.26 ± 0.08 log, 1.55 ± 0.23 log, 6.38 ± 0.28 log 244 
and 7.83 ± 0.67 log are obtained for concentrations of 5x MIC, 10x MIC, 20x MIC and 30x MIC, 245 
respectively.  Comparison of the effect of 30x MIC Art-175 in the presence (Figure 1C) and absence 246 
(Figure 1D) of 0.5 mM EDTA shows that EDTA mainly has an accelerating effect and the extent of 247 
killing after 2 h is similar. Also stationary phase cells of RUH875 and NCTC 13423 can be completely 248 
eradicated within 24 h with Art-175 (20x MIC) in the absence of EDTA, whereas LUH5875 is slightly 249 
less affected with a decrease in surviving cell number of 6.93 ± 0.49 log (data not shown). 250 
 251 
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Real-time time lapse microscopy shows bactericidal effect upon contact 252 
The rapid bactericidal effect of Art-175 previously hindered real-time monitoring of the mode-of-253 
action, unless Art-175 was sufficiently diluted (14). Therefore, a flow cell was used to immobilize A. 254 
baumannii RUH134 cells in a microfluidic channel and the immobilized cells were monitored in real-255 
time when a flow of Art-175 (0.4 mg/ml) made contact (Figure 2A; Movie S1A). All cells lysed 256 
immediately in the first frame (3 sec) and the cell contents were dispersed in the flow of Art-175 257 
solution. This clearly demonstrates that Art-175 can act upon contact. Cells were resuspended in a 258 
buffer with low ionic strength (20 mM HEPES-NaOH pH 7.4), resulting in a high internal osmotic 259 
pressure and thus likely contributing to a drastic lysis phenomenon. In a similar experiment but with 260 
cells resuspended in a buffer with high ionic strength (20 mM HEPES-NaOH pH 7.4 supplemented with 261 
0.5 M NaCl) and a lowered Art-175 concentration, different observations were made (Figure 2B; 262 
Movie S1B). Lysis took place again, but was slower (<1 h) and the cells first adopted a spherical shape 263 
before becoming unstable and lysing. Under these conditions, the contribution of two separate 264 
effects caused by Art-175 could be visualized, i.e. peptidoglycan degradation resulting in the adoption 265 
of a spherical shape and osmotic lysis due to the lack of a protective cell wall. 266 
 267 
Art-175 is a highly efficient anti-persister compound 268 
Persister cells constitute a small sub fraction of the bacterial population transiently tolerant to 269 
treatment with high doses of antibiotics (6). Art-175 is capable of completely eradicating the persister 270 
fraction of P. aeruginosa (14). This effect can be attributed to the mode of action of Artilysin®s that 271 
physically cleave the peptidoglycan, instead of inhibiting an essential step in the metabolism. 272 
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Consequently, there is no need for an active metabolism, making them very suitable for the 273 
elimination of persister cells (14). To investigate whether the anti-persister effect of Art-175 is broadly 274 
conserved, A. baumannii RUH134 persister cells were isolated through 5 h treatment with high doses 275 
of tobramycin. After isolation, the remaining fraction was treated for 1 h with a concentration 276 
corresponding to 30x MIC of ciprofloxacin or Art-175, respectively, in the absence or presence of 0.5 277 
mM EDTA. In addition, equimolar amounts of the endolysin KZ144 alone were tested. As controls, 278 
treatments with 20 mM HEPES-NaOH pH 7.4 (storage buffer), 0.5 mM EDTA and 30xMIC tobramycin 279 
were included. 280 
The isolated persister cells could not be killed by a new tobramycin exposure, confirming that the 281 
actual persister subfraction was isolated. Controls such as the storage buffer, EDTA, and ciprofloxacin 282 
cause a small but significant reduction of the persister fraction, which may be best explained by the 283 
occasional waking up of persister cells during sequential washing steps. Treatment of the persister 284 
cells with 30x MIC Art-175, in the absence or presence of 0.5 mM EDTA, significantly reduced the 285 
remaining persister fraction with 2.35 ± 0.42 log and 2.66 ± 0.45 log, respectively. Under these 286 
conditions, EDTA did not significantly enhance the anti-persister effect. KZ144, on the other hand, 287 
caused reductions of only 1.24 ± 0.43 log and 1.93 ± 0.49 log in the absence and presence of 0.5 mM 288 
EDTA, respectively (Figure 3). 289 
In conclusion, Art-175 reduces the surviving persister fraction most compared to the controls, 290 
demonstrating a potent anti-persister effect. Although the occurrence of persister cells has been 291 
described in A. baumannii (5, 25), Art-175 and KZ144 are, to our knowledge, the first antibacterial 292 
compounds described to exert an anti-persister effect against A. baumannii.  293 
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 294 
Art-175 shows no hemolytic activity 295 
The antibacterial effect of SMAP-29 is explained by its membrane pore formation (26). Membrane 296 
pore formation requires oligomerization, and this effect is also correlated with the hemolytic activity 297 
of SMAP-29 (7.9% hemolysis at 50 µM or 0.16 ng/ml) (26). Although it is expected that SMAP-29 298 
oligomerization cannot take place in a fusion with the endolysin KZ144 due to steric hindrance, we 299 
have evaluated the hemolytic potential of Art-175 by assessing the damage of erythrocytes after 300 
exposure to Art-175. No hemolysis was observed for doses up to 200 µg/ml (100x MIC with 200 µM 301 
EDTA; 10-50x MIC without EDTA) in contrast to the positive controls Tween80 and Triton X-100 (data 302 
not shown).  303 
 304 
Resistance of A. baumannii against Art-175 cannot be provoked in vitro 305 
The rate of resistance development is an important parameter to evaluate the potential of a new 306 
antibacterial compound. A. baumannii is acknowledged as a multi-drug resistant organism, capable of 307 
developing resistance rapidly compared to other clinically relevant pathogens (27, 28). To analyze the 308 
resistance development of A. baumannii against Art-175, the epidemiological European reference 309 
strains (RUH134, RUH875 and LUH5875) were serially exposed to sub-inhibitory doses of Art-175. 310 
Ciprofloxacin was included as a control antibiotic.  A maximal two-fold increase of the MIC of Art-175 311 
was observed for all strains after 20 cycles (Figure 4B). In contrast, sub-inhibitory doses of 312 
ciprofloxacin resulted in the recovery of highly resistant strains (according to the breakpoints defined 313 
by EUCAST) of both RUH134 and RUH875 after 8 and 3 cycles, showing a 256- and 512-fold increase in 314 
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MIC value, respectively (Figure 4A). The MIC of RUH134 further developed to a 512-fold increase in 315 
cycle 14. For LUH5875 a four-fold increase in MIC was observed after 20 cycles. However, this strain 316 
already showed a relatively high initial resistance against ciprofloxacin, i.e., 85 µg/mL versus 1.3 317 
µg/mL (RUH134 and RUH875), corresponding to a 64-fold higher MIC. Resistance against Art-175 does 318 
not appear to be provoked through genetic mutations that are typically selected upon exposure to 319 
sub-inhibitory doses.  320 
Discussion 321 
A. baumannii causes a wide range of infections and is becoming an important risk in health care 322 
settings. Besides its great intrinsic resistance, extensive antibiotic use has fostered the selection for 323 
resistance against all known antimicrobials (28). Despite its increasing clinical relevance, few or no 324 
compounds are currently found in late stages of clinical development for the treatment of multidrug-325 
resistant A. baumannii infections (3). Increasing multidrug resistance in most bacterial pathogens and 326 
lack of new antibiotics have increased the need for alternative treatment options to combat these 327 
infections.  328 
The ability of purified, phage-derived endolysins to kill bacteria was discovered in 1959 and, over the 329 
years, research on phage endolysins and their ability as new antibacterials has greatly progressed (29, 330 
30). The unique nature of endolysins makes them highly attractive antibacterials for Gram-positive 331 
bacteria and provides several advantages over conventional antibiotics. Indeed, endolysins do not 332 
disturb the normal human microflora due to their high specificity, provide novel antimicrobial 333 
mechanisms, have a small chance of developing bacterial resistance and are able to kill colonizing 334 
pathogens on mucosal surfaces (31, 32). The potent effect of these phage encoded endolysins against 335 
different Gram-positive pathogens has been extensively reviewed (29, 33–35).  336 
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The majority of known endolysins is unable to cross the highly impermeable outer membrane of 337 
Gram-negative species. The engineering of endolysins towards Artilysin®s allowed us to overcome this 338 
barrier. Optimized fusions of phage endolysins with a peptide component capable of guiding the 339 
endolysin through the bacterial outer membrane results in a strong bactericidal effect against Gram-340 
negative pathogens (11). Previous work described the development of Art-085 and its optimized 341 
homolog Art-175, composed of a fusion between the SMAP-29 peptide and the N-terminus of the full-342 
length KZ144 endolysin containing three Cys→Ser mutations. Art-175 proved very successful in the 343 
eradication of P. aeruginosa and its persister cells, and its potent antibacterial activity has since then 344 
been demonstrated in vivo in dogs (11, 13, 14). The success of Art-175 prompted us to further expand 345 
and verify this Artilysin® as a novel antimicrobial for the treatment of A. baumannii, another clinically 346 
relevant pathogen within the order of the Pseudomonadales. 347 
Compounds showing a broad activity without displaying cross-resistance with existing drug resistance 348 
mechanisms show great promise as novel antibacterials. Therefore, a diverse panel of thirty-three A. 349 
baumannii strains, including strains from different origins and with different antibiotic susceptibilities 350 
was evaluated. Art-175 inhibits the growth of all these strains (MIC between 4 and 20 µg/ml). No 351 
correlation between the MIC value of Art-175 and the source, isolation site, resistance spectrum 352 
(aminoglycosides, quinolones and carbapenems) and the MIC value for colistin was observed, 353 
demonstrating the lack of cross-resistance and the broad activity of Art-175. Addition of 0.2 mM EDTA 354 
generally reduces the MIC value. 355 
Four epidemiological reference strains that are resistant towards at least two classes of first-line 356 
antibiotics (aminoglycosides, quinolones and carbapenems) were selected for further studies to 357 
evaluate the in vitro efficiency of Art-175. In time-kill experiments, Art-175 shows a significantly 358 
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increased reduction of cell number compared to two conventional antibiotics, ciprofloxacin and 359 
tobramycin. All therapeutics show a strain-dependent killing rate but a single dose of Art-175 360 
eradicates stationary phase cells of all bacterial strains within 24 h (between 8 and 9 log reduction). 361 
Different endolysins have been reported to have intrinsic antibacterial activity without the need for 362 
engineering, especially against A. baumannii (36, 37). The outer membrane of A. baumannii therefore 363 
appears to be less a barrier for large enzyme molecules than in other Gram-negative species. 364 
Endolysin PlyF307 derived from an A. baumannii prophage is effective against exponentially growing 365 
A. baumannii cells (>3 log units), but its activity is reduced when stationary phase cells are exposed to 366 
the antibacterial (approximately 1.5 log unit) (38). In fact, endolysins have been reported to be 367 
generally less active against stationary phase cells when compared to logarithmically growing cells 368 
(39). The complete elimination of stationary phase cells by Art-175, partially due to its anti-persister 369 
activity, is therefore one of the most remarkable features of Art-175. 370 
Combination therapy has often been suggested for the treatment of Gram-negative infections, 371 
including A. baumannii (40, 41). Combinations of endolysins and antibiotics have been reported to be 372 
superior to antibiotics alone (42). To evaluate the potential of Art-175 as a supplement to existing 373 
antibiotic therapies, Art-175 was combined with ciprofloxacin and tobramycin, and its effect was 374 
compared to monotherapy. 375 
The combined therapy results in an improved antibacterial effect for both mixtures, as compared to 376 
conventional antibiotic monotherapy. However, there is no significant improvement compared to Art-377 
175 alone, suggesting that Art-175 kills the bacterial cells before either ciprofloxacin or tobramycin 378 
can exert their action.   379 
19 
 
The rapid mode of action of Art-175 is confirmed with the complete eradication of RUH134 380 
(approximately 9 log reduction) after 2 hours of treatment, outcompeting both ciprofloxacin and 381 
tobramycin. A low concentration of EDTA, which chelates divalent cations that contribute to the 382 
stabilization of the outer membrane, further accelerates the killing rate. We introduced the use of 383 
microfluidic flow cells to immobilize bacteria to allow real-time observation. Using this method, we 384 
show that an immediate, rapid and intense lysis takes place. Under low osmotic pressure conditions 385 
(high ionic strength of the medium) and a lowered concentration of Art-175, the mode of action of 386 
Art-175 can be visualized in slow motion with the full enzymatic degradation of the shape-387 
determining peptidoglycan sacculus followed by a destabilization of the cell and spontaneous lysis. 388 
Enzymatic degradation of the peptidoglycan layer is only possible when Art-175 has first passed the 389 
outer membrane. Since the endolysin KZ144 is not able to pass the outer membrane efficiently, this 390 
can be only explained by the fused SMAP-29 moiety that interferes with the electrostatic interactions 391 
between adjacent LPS molecules. This is in contrast to the receptor-mediated uptake mechanism as 392 
described for a chimeric endolysin, comprising the FyuA binding domain fused to the N-terminus of T4 393 
lysozyme. This hybrid protein kills Yersinia and pathogenic E. coli strains, which express the FyuA 394 
receptor (43). Once passed the outer membrane, enzymatic degradation takes place, resulting in a 395 
rod to sphere transformation. Nevertheless, loss of the cell wall does not necessarily kill the cell, as 396 
has been extensively described for cell wall-deficient bacteria or L-forms, which are able to survive 397 
and even multiply if there is an appropriate isotonic environment (44, 45). The peptidoglycan layer 398 
can also be removed by peptidoglycan degrading enzymes (such as the commonly used hen egg white 399 
lysozyme) to prepare so-called protoplasts. These ‘naked’ cells remain viable, are competent to take 400 
up extracellular DNA and can reconstruct an intact cell wall after transformation. This process 401 
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requires that the cells are resuspended in an isotonic solution, i.e. a solution with the same osmolarity 402 
as inside the cell to eliminate the cellular osmotic pressure. This technique is commonly used in 403 
molecular microbiology to modify the genetic content of a bacterial cell. Therefore, the actual cause 404 
of death can be defined as a physical process called osmotic lysis. Depending on the osmolarity of the 405 
medium, we propose that osmotic lysis will take place immediately or only after extensive 406 
peptidoglycan degradation until the cells get too much destabilized by the internal osmotic pressure. 407 
Given this dependence on osmolarity, it would be interesting to evaluate Art-175 under serum 408 
conditions in future. 409 
The presence of so-called persister cells is increasingly being recognized as an important cause of the 410 
chronic nature of bacterial infections (46, 47). Despite being a clinically relevant pathogen known to 411 
cause chronic infections, the observation of the persister phenotype in this species has only recently 412 
been described. 94.6% of the tested clinical isolates showed a detectable persister fraction, varying 413 
between 0.0007% and 10.1%, indicating that the persister phenotype is broadly distributed amongst 414 
A. baumannii strains (5). Unlike most traditional antibiotics, Art-175 does not require an active 415 
metabolism to exerts its antibacterial activity, making it an ideal candidate for novel anti-persister 416 
therapies. Treatment of stationary phase cultures of A. baumannii with high doses of tobramycin 417 
confirmed the presence of a persister fraction in RUH134 of about 0.0004%. Exposure of this isolated 418 
persister fraction to Art-175 (+ 0.5 mM EDTA) results in an efficient 2.4 log (2.7 log) reduction in 419 
surviving cells. However, in case of P. aeruginosa persisters, a complete elimination of the persister 420 
fraction could be achieved with similar doses. Despite the clear clinical relevance of persister cells, 421 
anti-persister therapies described in literature are still limited, Art-175 being the first molecule, to our 422 
knowledge, exerting an activity against A. baumannii persister cells. 423 
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No resistance development is observed after serial exposure of three different A. baumannii strains to 424 
sub-inhibitory concentrations of Art-175. On the contrary, repeated exposure to ciprofloxacin, a first-425 
line antibiotic in healthcare settings, results in the quick recovery of highly resistant strains for both 426 
RUH875 and RUH134 with 512- and 265-fold increases in MIC values, respectively. Similar findings 427 
have been reported for endolysins (48, 49). The immutable nature of peptidoglycan and the high 428 
selection pressure for endolysin optimization during the long and intense co-evolution between 429 
phages and bacteria have been proposed as explanations for similar observations with endolysins and 430 
appear to hold true for Artilysin®s (14). Also, the ‘extracellular’ location of peptidoglycan excludes 431 
many potential resistance mechanisms such as efflux pumps and inactivation of the antibacterial (34).  432 
In conclusion, Art-175 shows high and rapid in vitro bactericidal activity against two of the most 433 
dangerous Gram-negative pathogens posing risks to our current health care systems, A. baumannii 434 
and P. aeruginosa, both belonging to the order of Pseudomonadales. Art-175 clearly differentiates 435 
from other classes of antibiotics both in completeness of killing (including persisters), killing rate and 436 
the mode of action. 437 
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FIGURE legends 600 
Figure 1: Antibacterial effect of Art-175 and combinations of conventional antibiotics with Art-175 601 
on different A. baumannii reference strains. Stationary phase cultures of respectively RUH875 602 
(black), LUH5875 (dark grey), NCTC 13423 (light grey) and RUH134 (white) were treated for (A) 1 hour 603 
or (B) 24 hours with ciprofloxacin (15 µg/mL), tobramycin (60 µg/mL), Art-175 (60 µg/mL) or the 604 
combination therapy of Art-175 with these antibiotics. All concentrations correspond to a 30x MIC 605 
value. Bacterial survival after 1 h and 24 h treatment is expressed in log10 (CFU/ml). ND = not 606 
detected. (C) Time-kill curves were obtained for RUH134 with stationary phase cells that were treated 607 
for 20 min, 40 min, 1 h or 2 h with buffer (control, black line), ciprofloxacin (filled circle; 15 µg/mL), 608 
ciprofloxacin + Art-175 (open circle; 15 µg/mL and 120 µg/mL respectively), tobramycin (filled 609 
triangle; 60 µg/mL), tobramycin + Art-175 (open triangle; 60 µg/mL and 120 µg/mL, respectively) or 610 
Art-175 (open diamond; 120 µg/mL). All concentrations correspond to a 30x MIC value. Data points 611 
represent the mean  value (± SEM) of at least three independent repeats. (D) Stationary phase cells of 612 
RUH134 were treated with increasing concentrations of Art-175 for 20 min, 40 min, 1h and 2h. The 613 
control consists of buffer (black line), Art-175 was administered in 5x MIC (open circles; 20 µg/mL), 614 
10x MIC (open triangles; 40 µg/mL), 20x MIC (open squares; 80 µg/mL) and 30x MIC (open diamonds; 615 
120 µg/mL) concentrations. Data points represent the mean value (± SEM) of three independent 616 
repeats. 617 
 618 
Figure 2: Real-time monitoring of osmotic lysis induced by Art-175. Exponential phase cells of A. 619 
baumannii RUH134 with (A) a high internal osmotic pressure (washed with 20 mM HEPES-NaOH pH 620 
7.4 0.5 mM EDTA) or (B) a low internal osmotic pressure  (washed with 20 mM HEPES-NaOH pH 7.4 621 
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0.5 M NaCl 0.5 mM EDTA) were immobilized in a flow cell and exposed to Art-175 (0,4 mg/ml with 0.5 622 
mM EDTA). A time-lapse series is presented with intervals of (A) 3 sec or B) 5 min. To visualize the 623 
rapid lysis under high osmotic pressure conditions, three frames before contact with Art-175 are 624 
shown (from -00:00:06). The flow of Art-175 is started at 00:00:00). Total duration is (A) 36 seconds 625 
and (B) 1 h . Scale bars correspond to 2 µm. Movie S1A and S1B show the full time-lapse series. 626 
 627 
Figure 3: Art-175 kills isolated persister cells. Stationary phase cultures of RUH 134 were treated with 628 
high doses of tobramycin to isolate the surviving persister fraction. The remaining persister cells were 629 
treated with 30x MIC concentrations of ciprofloxacin (15 µg/mL), Art-175 (120 µg/mL) and an 630 
equimolar dose of KZ144 (108 µg/mL), all in the absence and presence of 0.5 mM EDTA. As a control, 631 
untreated persister cells and treatment with 0.5 mM EDTA and 30x MIC tobramycin (60 µg/mL) were 632 
taken into account. Persister survival after 5 hours is expressed in log10 (CFU/ml). Mean values are 633 
shown (± SEM) for at least 3 independent repeats. 634 
 635 
Figure 4: Art-175 is highly refractory to resistance development. A. baumannii strains RUH134 636 
(triangle), RUH875 (circle) and LUH5875 (square) were serially treated with sub-inhibitory 637 
concentrations of (A) ciprofloxacin or (B) Art-175 to select for decreased susceptibility. Values are 638 
represented as the ratio of the MIC value after cycle i (MICi) over the MIC value at the start of the 639 
experiment (MIC0). After 20 cycles, the MIC of Art-175 increased maximally twofold, whereas the MIC 640 
of ciprofloxacin increased 512- (RUH134 and RUH875) or 4-fold (LUH5875). 641 
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